Table 1.
Characteristics of 109 newly diagnosed patients with AML.
| Group | Subgroup | Number | Group | Subgroup | Number |
|---|---|---|---|---|---|
| Gender | Male | 62 | Cross lineage | Yes | 37 |
| Female | 47 | No | 72 | ||
| Age | <60 y (14-59) | 58 | Karyotype | Low risk | 28 |
| ≥60 y (60-91) | 51 | Medium risk | 47 | ||
| FAB classification | M0 | 1 | High risk | 15 | |
| M1 | 4 | No data | 19 | ||
| M2 | 33 | Fusion gene | RUNX1-RUNX1T1 | 9 | |
| M3 | 19 | PML/RARα | 16 | ||
| M4 | 20 | CBFβ-MYH11 | 5 | ||
| M5 | 9 | Others | 79 | ||
| M6 | 1 | Gene mutation | FLT3-ITD | 9 | |
| Mu | 22 | CEBPA | 6 | ||
| WBC | Low | 24 | NMP1 | 5 | |
| Middle | 26 | C-kit | 3 | ||
| High | 59 | Others | 86 | ||
| AML type | De novo | 93 | First induction | CR | 35 |
| Secondary | 16 | Non-CR | 27 | ||
| Extramedullar | Yes | 13 | Curative effect | CCR | 27 |
| No | 96 | R/R | 35 |
Note: AML: acute myeloid leukemia; FAB: Franch-American-Britain; Mu: unclassifiable AML in morphology; WBC: white blood cell; CR: complete remission; Non-CR: not complete remission; CCR: continued complete remission; R/R: relapse/refractory.